Patient and graft characteristics (n = 106)
| Variable . | Value . |
|---|---|
| Median age (range), y | 50 (22-70) |
| Male, n (%) | 55 (52) |
| Median weight (range), kg | 80 (36-138) |
| Recipient CMV+, n (%) | 59 (56) |
| Diagnosis, n (%) | |
| Acute leukemia (AML/ALL/other) | 70 (66) |
| MDS/MPN | 14 (13) |
| Lymphoma (NHL/HD) | 22 (21) |
| Conditioning, n (%)* | |
| High intensity | 1 (1) |
| Intermediate intensity | 101 (95) |
| Nonmyeloablative | 4 (4) |
| Donor-recipient 8-allele HLA match,† median (range) | 5 (3 to 7) |
| Infused TNC dose × 107/kg,† median (range) | 2.35 (1.23-5.31) |
| Infused viable CD34+ dose × 105/kg,† median (range) | 1.18 (0.18-4.08) |
| Infused viable CD3+ dose × 106/kg,† median (range) | 3.34 (0.45-10.61) |
| Graft composition, n (%)‡ | |
| dCB | 45 (42) |
| dCB-haploCD34+ | 59 (56) |
| sCB-haploCD34+ | 2 (2) |
| Variable . | Value . |
|---|---|
| Median age (range), y | 50 (22-70) |
| Male, n (%) | 55 (52) |
| Median weight (range), kg | 80 (36-138) |
| Recipient CMV+, n (%) | 59 (56) |
| Diagnosis, n (%) | |
| Acute leukemia (AML/ALL/other) | 70 (66) |
| MDS/MPN | 14 (13) |
| Lymphoma (NHL/HD) | 22 (21) |
| Conditioning, n (%)* | |
| High intensity | 1 (1) |
| Intermediate intensity | 101 (95) |
| Nonmyeloablative | 4 (4) |
| Donor-recipient 8-allele HLA match,† median (range) | 5 (3 to 7) |
| Infused TNC dose × 107/kg,† median (range) | 2.35 (1.23-5.31) |
| Infused viable CD34+ dose × 105/kg,† median (range) | 1.18 (0.18-4.08) |
| Infused viable CD3+ dose × 106/kg,† median (range) | 3.34 (0.45-10.61) |
| Graft composition, n (%)‡ | |
| dCB | 45 (42) |
| dCB-haploCD34+ | 59 (56) |
| sCB-haploCD34+ | 2 (2) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HD, Hodgkin disease; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma.
High-intensity myeloablative conditioning was with cyclophosphamide 120 mg/kg, fludarabine 75 mg/m2, and total body irradiation (TBI) 1320 cGy; intermediate-intensity myeloablative was with cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 5 to 10 mg/kg, and TBI 400 cGy33 ; nonmyeloablative included cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, and TBI 200 cGy (n = 3), or fludarabine 150 mg/m2 and TBI 400 cGy (n = 1).
Engrafting CB unit.
Fifty-nine double-unit CB (dCB) grafts and 2 single-unit CB (sCB) grafts were supplemented with haploidentical CD34+ cells to provide a myeloid bridge prior to CB engraftment.